114 related articles for article (PubMed ID: 37734383)
1. Palbociclib releases the latent differentiation capacity of neuroblastoma cells.
Ferguson KM; Gillen SL; Chaytor L; Poon E; Marcos D; Gomez RL; Woods LM; Mykhaylechko L; Elfari L; Martins da Costa B; Jamin Y; Carroll JS; Chesler L; Ali FR; Philpott A
Dev Cell; 2023 Oct; 58(19):1967-1982.e8. PubMed ID: 37734383
[TBL] [Abstract][Full Text] [Related]
2. The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.
Vrenken KS; Vervoort BMT; van Ingen Schenau DS; Derks YHW; van Emst L; Grytsenko PG; Middelbeek JAJ; van Leeuwen FN
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165644. PubMed ID: 31862304
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
[TBL] [Abstract][Full Text] [Related]
4. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
5. Sub-micromolar concentrations of retinoic acid induce morphological and functional neuronal phenotypes in SK-N-SH neuroblastoma cells.
Harasym E; McAndrew N; Gomez G
In Vitro Cell Dev Biol Anim; 2017 Oct; 53(9):798-809. PubMed ID: 28840512
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid and evernyl-based menadione-triazole hybrid cooperate to induce differentiation of neuroblastoma cells.
Mendonza JJ; Reddy ST; Dutta H; Makani VKK; Uppuluri VM; Jain N; Bhadra MP
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2651-2665. PubMed ID: 37097334
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Luo P; Lin M; Li L; Yang B; He Q
PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
[TBL] [Abstract][Full Text] [Related]
10. Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations.
Das A; Alshareef M; Martinez Santos JL; Porto GBF; McDonald DG; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2020 Nov; 22(11):2017-2025. PubMed ID: 32253706
[TBL] [Abstract][Full Text] [Related]
11. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
12. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements.
Illendula A; Fultang N; Peethambaran B
Oncol Rep; 2020 Sep; 44(3):1013-1024. PubMed ID: 32705280
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
16. p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation.
Borriello A; Pietra VD; Criscuolo M; Oliva A; Tonini GP; Iolascon A; Zappia V; Ragione FD
Oncogene; 2000 Jan; 19(1):51-60. PubMed ID: 10644979
[TBL] [Abstract][Full Text] [Related]
17. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(β-TRCP) in neuroblastoma cells.
Singh A; Rokes C; Gireud M; Fletcher S; Baumgartner J; Fuller G; Stewart J; Zage P; Gopalakrishnan V
Cancer; 2011 Nov; 117(22):5189-202. PubMed ID: 21523764
[TBL] [Abstract][Full Text] [Related]
19. TOP2B Is Required to Maintain the Adrenergic Neural Phenotype and for ATRA-Induced Differentiation of SH-SY5Y Neuroblastoma Cells.
Khazeem MM; Casement JW; Schlossmacher G; Kenneth NS; Sumbung NK; Chan JYT; McGow JF; Cowell IG; Austin CA
Mol Neurobiol; 2022 Oct; 59(10):5987-6008. PubMed ID: 35831557
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid arrests neuroblastoma cells in a dormant state. Subsequent nerve growth factor/brain-derived neurotrophic factor treatment adds modest benefit.
Cernaianu G; Brandmaier P; Scholz G; Ackermann OP; Alt R; Rothe K; Cross M; Witzigmann H; Tröbs RB
J Pediatr Surg; 2008 Jul; 43(7):1284-94. PubMed ID: 18639684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
